key: cord-0836437-5zqkpswg
authors: Lew, Tedrick Thomas Salim; Aung, Khin Moh Moh; Ow, Sian Yang; Amrun, Siti Naqiah; Sutarlie, Laura; Ng, Lisa F. P.; Su, Xiaodi
title: Epitope-Functionalized Gold Nanoparticles for Rapid and Selective Detection of SARS-CoV-2 IgG Antibodies
date: 2021-06-16
journal: ACS Nano
DOI: 10.1021/acsnano.1c04091
sha: e3113c3c5965bcb735eb5984e83402f244078a30
doc_id: 836437
cord_uid: 5zqkpswg

[Image: see text] Rapid and inexpensive immunodiagnostic assays to monitor severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion are essential for conducting large-scale COVID-19 epidemiological surveillance and profiling humoral responses against SARS-CoV-2 infections or immunizations. Herein, a colorimetic serological assay to detect SARS-CoV-2 IgGs in patients’ plasma was developed using short antigenic epitopes conjugated to gold nanoparticles (AuNPs). Four immunodominant linear B-cell epitopes, located on the spike (S) and nucleocapsid (N) proteins of SARS-CoV-2, were characterized for their IgG binding affinity and used as highly specific biological motifs on the nanoparticle to recognize target antibodies. Specific bivalent binding between SARS-CoV-2 antibodies and epitope-functionalized AuNPs trigger nanoparticle aggregation, which manifests as a distinct optical transition in the AuNPs’ plasmon characteristics within 30 min of antibody introduction. Co-immobilization of two epitopes improved the assay sensitivity relative to single-epitope AuNPs with a limit of detection of 3.2 nM, commensurate with IgG levels in convalescent COVID-19-infected patients. A passivation strategy was further pursued to preserve the sensing response in human plasma medium. When tested against 35 clinical plasma samples of varying illness severity, the optimized nanosensor assay can successfully identify SARS-CoV-2 infection with 100% specificity and 83% sensitivity. As the epitopes are conserved within the circulating COVID-19 variants, the proposed platform holds great potential to serve as a cost-effective and highly specific alternative to classical immunoassays employing recombinant viral proteins. These epitope-enabled nanosensors further expand the serodiagnostic toolbox for COVID-19 epidemiological study, humoral response monitoring, or vaccine efficiency assessment.

T he ongoing pandemic caused by SARS-CoV-2 underscores the need for rapid, accurate, and cost-effective diagnostic assays to contain the spread of COVID-19 at national and global scales. In addition to molecular and antigen tests, serological assays play a key role in enabling timely management and effective response to combat pandemic outbreaks. 1 Such tests detect antibodies produced due to SARS-CoV-2 infection, which are detectable as early as 2 days after symptom onset in some patients. 2, 3 Since antibodies persist much longer than viral RNA or antigens in biological fluids, their presence can inform current exposure, disease progression, and past infection or immunity. 4 As such, serological testing has been crucial in epidemiological surveillance to identify SARS-CoV-2-infected individuals who may not have been diagnosed due to asymptomatic infection or mild illness, providing important information to better understand COVID-19 transmission dynamics. 5, 6 Immunolog-ical assays can also complement antigen or molecular tests particularly at the later stage of infection, where viral load is reduced significantly upon shedding and seroconversion. 7−9 Additionally, as doses of COVID-19 vaccines have been administered in many countries, serology assays can be a key tool to evaluate vaccine efficiency and humoral response kinetics postvaccination. 10−12 To date, most serological tests to detect SARS-CoV-2specific antibodies are based on enzyme-linked immunoab-sorbent assays (ELISA) or chemiluminescent assays (CLIA) employing two recombinant coronavirus proteins: the S glycoprotein and the N phosphoprotein. 13, 14 However, the use of recombinant full-length viral proteins may result in ambiguous detection outcome due to cross-reactivity with phylogenetically similar viruses. 17 In particular, both the S and N proteins share a high homology with other human coronaviruses (hCoVs); for instance, they show 76% and 90% sequence similarity with SARS-CoV S and N proteins, respectively. 15 This sequence homology contributes to significant cross-reactivity in serological tests employing recombinant viral proteins. 16 Full-length recombinant antigens may also suffer from batch-to-batch variations and stability problems during storage and transport, affecting the reproducibility of serological immunoassays. 17 Alternatively, short antigenic epitopes have emerged as promising substitutes of recombinant proteins in immunoassays. Besides benefiting from well-established peptide chemistry, ease of purification, and high stability, the use of peptide epitopes provides a distinctive capacity to break down heterogeneous immune responses into almost monoclonal antibody specificities, enabling a highly differentiated serological diagnosis. 18, 19 We have recently reported the discovery of four IgG-specific linear B-cell epitopes that could differentiate SARS-CoV-2 from other coronavirus infections using COVID-19 patients' plasma samples. 20, 21 These peptide epitopes are conserved within the circulating COVID-19 variants 20 and thus have the potential to serve as highly specific affinity ligands for improved immunoassay development. In terms of assay formats, classical immunoassays are labor-intensive and require multiple reagents with long incubation, washing, and reaction steps (2−5 h). 22 Currently, the development of a cost-effective serological assay that can provide simple, fast, and specific determination of SARS-CoV-2 antibodies with minimal Figure 1 . Characterization of the binding affinity and specificity of four SARS-CoV-2 linear B-cell epitopes. Schematic depiction of (a) SPR spectroscopy and (b) FP working principles to characterize the epitopes' binding affinity and specificity toward SARS-CoV-2 IgG. (c) SPR sensorgram data showing real-time binding of anti-SARS-CoV-2 S1 IgG at varying concentrations to the immobilized S14P5 epitope. Dashed line represents model fit. (d) Relative FP increase when 100 nM peptide epitopes were treated with 200 nM SARS-CoV-2, SARS-CoV, and normal human IgGs. Two-tailed unpaired t-tests, ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, ns = not significant, compared with SARS-CoV-2 IgG treatment for each epitope. Data represent mean ± standard deviation from 3 independent experiments.

www.acsnano.org Article equipment remains an unmet need in immunological diagnosis. Several nanotechnology-based approaches have emerged as promising diagnostic tools for rapid and accessible detection of SARS-CoV-2 viral RNA, antigen, and related biomarkers. 23−26 In particular, gold nanoparticles (AuNPs) have been increasingly used in SARS-CoV-2 diagnostic platforms due to their notable optical properties such as high extinction coefficients and tunable localized surface plasmon resonance (LSPR), enabling a distinct color readout with a simple equipment or the naked eye. 27−31 For SARS-CoV-2 antibody detection (IgG, IgM, or IgA), AuNP-and fluorescent nanoparticle-based assays have been proposed, but all of them currently rely on the use of recombinant viral proteins to recognize the target antibody. 32−36 Most of these platforms also employ antihuman antibodies as capture or reporter reagents in sandwich assays. However, this strategy intrinsically reduces the assay sensitivity because non-SARS-CoV-2-specific antibodies are abundant in blood (IgG: 7−16 g/L; IgM: 0.4− 2.3 g/L), and they may compete with target SARS-CoV-2 antibodies for binding with antihuman antibody reagents. 37, 38 In this study, we demonstrate the development of an AuNPbased colorimetric assay to detect SARS-CoV-2-specific IgG antibodies by utilizing recently identified linear B-cell epitopes located on the S and N proteins of SARS-CoV-2. 20, 21 This hybrid nano−bio sensor concept exploits both the distancedependent optical properties of AuNPs and the natural IgG recognition ability of immunodominant epitopes to enable a rapid serological assay without the use of recombinant viral proteins or antihuman antibodies. Since IgG antibodies are homobivalent molecules, the binding of epitopes, immobilized on the nanoparticle surface, to their cognate IgG paratopes can trigger interparticle bridging, which manifests as changes in the optical property of AuNPs. We first characterize the binding affinity of four putative epitopes toward their cognate SARS-CoV-2 IgG with surface plasmon resonance (SPR) and fluorescence polarization (FP) techniques. Thereafter, we develop a generic conjugation approach to ensure successful attachment of epitopes bearing different charges on AuNPs. The nanosensor design is subsequently optimized for selective and sensitive recognition of the target antibodies. Finally, we verify the practical utility of the proposed nanosensor assay with 35 clinical samples, confirming that plasma fractions from COVID-19-infected patients elicited distinctively higher sensor response than those obtained from healthy individuals. In addition to the utility of the proposed platform for SARS-CoV-2 serodiagnostics, the nanosensor design principles outlined here can be potentially extended to other antigenic epitopes for the development of rapid immunoassays in current and future pandemics.

Biophysical Characterization of Epitopes' Binding Affinity and Specificity. Our nanosensor-based platform is inspired by previous discovery of four immunodominant B-cell linear epitopes, namely, S14P5, S20P2, S21P2, and N4P5, which were identified as antigenic targets of IgGs present in the plasma samples of COVID-19 patients. 20 These four epitopes are 18 amino acids in size, and they are located on the S and N viral proteins of SARS-CoV-2 (Table 1 ). Since the epitopes are located on different viral protein subunits responsible for specific biological functions, it is important to characterize the IgG binding affinity of each peptide. While these epitopes have been screened against plasma samples of COVID-19 patients collected in Singapore using peptide-based ELISA, their binding characteristics toward epitope-specific IgGs of SARS-CoV-2 have not been investigated. Herein, we first determined the binding affinity and specificity of the four epitopes by using two distinct biophysical characterization tools, specifically SPR spectroscopy and the FP technique (Figure 1a and b) . SPR spectroscopy detects binding between immobilized ligands and target analytes at the surface of a thin metal film via changes in the refractive index. 40, 41 It allows for a label-free, quantitative, and real-time measurement to obtain the binding kinetic constants and affinity. SPR sensorgram data confirmed the binding of all four epitopes when titrated against varying concentrations of epitope-specific SARS-CoV-2 IgGs (Figure 1c and Figure S1 ). Global fitting of kinetic binding data with a 1:1 Langmuir model yielded equilibrium dissociation constants (K d ) of approximately 80 and 218 nM for S20P2 and N4P5 epitopes, respectively (Table 2 ).

However, the K d values of S14P5 and S21P2 could not be exactly determined from this kinetic analysis, as these two epitopes exhibit a very slow dissociation step from their respective IgG targets, resulting in an apparent K d in the low pM range beyond the instrument sensitivity limit. 42, 43 As such, steady-state analysis without a dissociation step was performed to obtain steady-state K d values ( Figure S2 and Table 2 ). Both kinetic and steady-state analysis confirmed that among the four peptides, S14P5 and S21P2 epitopes exhibit the highest binding affinity toward their respective target IgGs of SARS-CoV-2, followed by S20P2 and then the N4P5 epitope.

An orthogonal FP approach was also pursued to determine the selectivity of these epitopes and to further confirm their IgG binding affinity. FP detects the binding of a fluorescent ligand (FITC-labeled epitopes, in this case) to a larger molecule (IgG) by measuring the increase in the polarization of fluorescence emission induced by the formation of a larger complex. 44 Compared to SPR spectroscopy, FP is a free solution technique that allows for high-throughput screening and does not require any separation of bound and free ligand. 45 The three S-protein-based epitopes (S14P5, S20P2, and S21P2) exhibited a significant increase in FP values upon the introduction of SARS-CoV-2 IgGs relative to the addition of the closely related SARS-CoV IgGs or the control normal human IgG (Figure 1d ). S14P5 exhibited the highest relative FP increase, followed by S21P2 and S20P2. Such a trend indicates specific binding between SARS-CoV-2 IgGs and the selected epitopes, with an affinity order that correlates well with that determined by the SPR spectroscopy. The N4P5 epitope showed a comparably lower percentage of FP increase against all IgGs, indicative of its low binding affinity and specificity. Its lowest response among the four epitopes corroborated earlier findings obtained from SPR measurements. Overall, biophysical characterization using both SPR spectroscopy and FP techniques confirmed that S14P5 and ACS Nano www.acsnano.org Article S21P2 epitopes are highly immunogenic, as previously reported. 21 The finding that N4P5 displayed the lowest binding affinity among the four putative epitopes was unexpected, as it showed the highest sensitivity in recognizing IgGs present in the plasma samples of SARS-CoV-2 patients. 20 This discrepancy might be due to the high titer of anti-N IgG in the plasma samples of SARS-CoV-2 patients tested or that the N4P5 epitope recognized only a small proportion of the polyclonal SARS-CoV-2 N rabbit antibodies employed in this study.

Preparation and Characterization of Epitope-Functionalized AuNPs. We next sought to investigate if these epitopes could serve as recognition moieties for SARS-CoV-2specific IgGs when conjugated to nanoparticles and if the epitope-IgG binding can trigger nanoparticle aggregation to alter AuNPs' plasmonic characteristics ( Figure 2a ). As shown in Table 1 , the four epitopes have different charges at psychological pH, with S20P2 peptide bearing a negative charge and the other peptides being positively charged. Previous studies have shown that directly conjugating positively charged peptides to negatively charged citratecapped AuNPs often jeopardizes the colloidal stability of nanoparticles due to electrostatic attractions and multipoint surface binding, limiting the efficacy and versatility of AuNP functionalization with peptides. 46, 47 It is thus desirable to construct a more universal platform for AuNP functionalization with epitopes of different charges. Streptavidin (SA) has been demonstrated to provide excellent protection of AuNPs and is known for its high affinity toward biotin via tetrameric binding sites, rendering its ideal use as both a stabilizer corona and a building block for conjugation of biotinylated biomolecules. 48 Taking advantage of the stabilizing property and connectivity of SA, we constructed a multilayered approach of conjugating biotinylated SARS-CoV-2 epitopes to SA-coated AuNPs (Figure 2a) . Considering that the surface area of 13 nm AuNPs is about 547 nm 2 per nanoparticle and the projected SA surface area is approximately 25 nm 2 , we estimate that a maximum of 22 SA molecules can be adsorbed per nanoparticle. 49 The concentration of SA was calculated to be above this close-packing threshold to ensure full surface coverage and minimize protein denaturation on the nanoparticle surface (see Methods). 50 Each biotinylated peptide epitope was then attached to the surface of AuNPs via the high-affinity SA−biotin binding, resulting in single-peptidefunctionalized AuNPs (hereafter denoted as S14P5-, S20P2-, S21P2-, and N4P5-AuNPs). Successful conjugation of SA and peptide epitopes to AuNPs was validated by the red-shift in the LSPR peak of AuNPs, from 520 nm in bare AuNPs to 530 and 534 nm after functionalization with SA and peptides, respectively (Figure 2b ). The average hydrodynamic diameters ). This hydrodynamic diameter further increased by approximately 5 nm upon the attachment of each of the SARS-CoV-2 peptide epitopes. The zeta potential of epitope-tagged AuNPs varies with the net charge of the epitopes as governed by their respective isoelectric point (pI) ( Figure S3 ). Additionally, SA-and epitope-functionalized AuNPs demonstrated higher colloidal stability in high ionic strength solution than bare AuNPs ( Figure S4 ), further validating the successful functionalization of SARS-CoV-2 epitopes on the AuNP surface. SARS-CoV-2 IgG Detection with Epitope-Tagged AuNPs. We next analyzed the change in the plasmonic characteristics of epitope-functionalized AuNPs upon mixing with target SARS-CoV-2 IgGs. S14P5-AuNPs were chosen for initial studies, as the S14P5 epitope exhibited the highest binding affinity among the four selected epitopes as characterized by SPR and FP techniques. This epitope is also located in close proximity to the receptor-binding domain (RBD) and showed high recognition toward SARS-CoV-2 patients with 97% sensitivity using peptide-based ELISA. 20, 21 The introduction of anti-SARS-CoV-2 S1 IgG elicited a dosedependent aggregation profile of S14P5-AuNPs, resulting in a decrease in the plasmon peak intensity (Figure 3a) . Such a response was absent when the nanoparticles were treated with normal human IgG and SARS-CoV anti-S IgG ( Figure S5 ). The anti-SARS-CoV-2 S1 IgG-induced nanoparticle aggregation could be conveniently observed by the naked eye ( Figure  3b ). From the absorbance spectrum, we note here that there is only a minor shift of the plasmon wavelength due to SARS-CoV-2 IgG treatment, indicating limited interparticle plasmonic coupling presumably because the interparticle distance between S14P5-AuNPs upon IgG binding is larger than the gold core diameter. 51, 52 Nonetheless, the specific antibodyinduced aggregation of S14P5-AuNPs was corroborated by transmission electron microscopy (TEM) images, which showed the clustering of nanoparticles in the presence of their target IgG (Figure 3c) . A steric−kinetic driving force, arising from spatial competition of IgGs for a limited number of epitopes on the AuNP surface, has been proposed as the mechanism underlying antibody-triggered aggregation of epitope-tagged AuNPs. 53 The response and kinetics of S14P5-AuNPs aggregation were monitored by analyzing the comparative decrease in peak absorbance at 534 nm at 10 min intervals for 60 min. When challenged with anti-SARS-CoV-2 S1 IgG, the normalized plasmon peak intensity of S14P5-AuNPs decreased by 40.2% in the first 10 min, leveling off to 67.3% within 30 min (Figure 3d) . Despite the high level of homology between the S protein of SARS-CoV-2 and SARS-CoV (76%), the normalized sensor response of S14P5-AuNPs ACS Nano www.acsnano.org Article was 6-fold lower (11.4%) when challenged with SARS-CoV IgG after 60 min. Taken together, these results highlight the rapid response and high selectivity of the S14P5 epitopefunctionalized AuNPs in discriminating SARS-CoV-2 IgG from other IgGs. The IgG dose-dependent responses of the other epitopefunctionalized AuNPs were analyzed to characterize their sensitivity. Although all four epitopes had been shown to display >95% sensitivity in detecting SARS-CoV-2 patients 23 days postillness onset (pio) with peptide-based ELISA, 20 we found that epitope-functionalized AuNPs exhibited vastly different levels of sensitivity in recognizing SARS-CoV-2specific IgGs (Figure 3e and Figure S6 ). In the order of their sensitivity, S14P5-AuNPs and S21P2-AuNPs showed a lower limit of detection (LOD) of 4.1 and 5.1 nM, respectively, while the LODs of S20P2-AuNPs and N4P5-AuNPs were higher, at 15.4 and 25.8 nM, respectively (see calculation in Methods). These figures of merit suggest that epitope-functionalized AuNPs can be potentially used to detect IgG in convalescent COVID-19 patient samples, in which IgG has been estimated to reach approximately 16.5 μg/mL (∼110 nM) at 21−25 days pio and remain at 11.4 μg/mL (∼76 nM) until 41 days pio. 54 Additionally, the sensitivity trend between the four epitopetagged AuNPs aligned with the binding affinity trend obtained from SPR spectroscopy characterization, confirming that the optical response of epitope-functionalized AuNPs arose from the IgG−epitope binding interaction.

We next fully assessed the selectivity of all four epitopefunctionalized AuNPs toward epitope-specific IgGs of the closely related SARS-CoV as well as two other human betacoronaviruses, namely, MERS and HCoV-HKU1 ( Figure  3f ). AuNPs functionalized with epitopes of the S1 and S2 protein subunits (S14P5-, S20P2-, and S21P2-AuNPs) showed minimal sensor response in the presence of MERS and HCoV-HKU1 IgGs. The minimal cross-reactivity may be due to the fact that these coronaviruses are only distantly related to SARS-CoV-2 at the protein level. 55 For the three S epitopes, the closely related SARS-CoV IgG elicited slightly higher level of attenuation in the nanoparticles' absorbance peak intensity compared to those elicited by the distantly related MERS and HCoV-HKU1 IgGs, but they are still substantially lower than the responses elicited by SARS-CoV-2 IgG. Among the four epitope-tagged AuNPs studied here, N4P5-AuNPs exhibited the lowest affinity and the highest cross-reactivity with IgGs of other human coronaviruses, with a similar degree of sensor response toward SARS-CoV-2 (15.4%) and SARS-CoV IgGs (14.9%). This cross-reactivity is not surprising, as the N protein of SARS-CoV-2 shares ∼90% homology in amino acid (c) Relative changes in plasmon peak intensity of nonpassivated and PEG-passivated AuNPs, functionalized with S14P5 alone or both S14P5 and S21P2 epitopes, against 100 nM anti-SARS-CoV-2 S1 IgG in different final concentrations of human plasma. Two-tailed unpaired t-tests, ***P < 0.001, **P < 0.01, *P < 0.05. Data represent mean ± standard deviation from 3 independent experiments. ACS Nano www.acsnano.org Article sequences with that of SARS-CoV. The N4P5 peptide itself also shares 94% sequence identity with the corresponding hit region on SARS-CoV N protein, the highest homology among the four epitopes studied here. 20 Nonetheless, for the other three epitopes, the highest sensor response for all peptide-AuNPs was elicited by SARS-CoV-2 IgGs, validating their choice as highly specific nanoparticle recognition moieties for the development of targeted SARS-CoV-2 serological assays. Conjugation of Dual Epitopes and Passivation Strategy. While the recognition affinity of each epitopetagged AuNP toward SARS-CoV-2 IgG has been demonstrated, we explored strategies to further improve the sensitivity and versatility of the nanosensor platform by coimmobilizing two different epitopes on the nanoparticle surface to form dual epitope-tagged AuNPs. The ability to conveniently attach multiple epitopes through facile nanoparticle functionalization for potentially improving assay performance represents a distinct advantage of epitope− nanoparticle platforms over conventional serological assays, most of which are based on single SARS-CoV-2 recombinant proteins. 14 As N4P5-AuNPs were found to be the least sensitive in detecting anti-SARS-CoV-2 IgG, we focused on the combinatorial use of S14P5, S20P2, and S21P2 epitopes. In particular, binary combinations of S14P5 with S20P2 or S21P2 epitopes were explored, as these pairs (S14P5/S20P2 and S14P5/S21P2) each contain epitopes located on both S1 and S2 protein subunits, potentially extending their capability to detect both anti-S1 and anti-S2 IgGs of SARS-CoV-2. As hypothesized, the dual-peptide-functionalized S14P5/S20P2-AuNPs and S14P5/S21P2-AuNPs were able to recognize both anti-S1 and anti-S2 IgGs of SARS-CoV-2, in contrast to the single-peptide-AuNPs, which could only recognize either anti-S1 or anti-S2 IgG ( Figure S7 ). The sensitivity of single-and dual-peptide AuNPs toward varying IgG concentrations was then juxtaposed through a heat map, in which a higher sensor response translates to a brighter color profile (Figure 4a ). Interestingly, both S14P5/S20P2-AuNPs and S14P5/S21P2-AuNPs could detect anti-SARS-CoV-2 S1 IgG with higher sensitivity (LODs of 4.0 and 3.2 nM, respectively) than AuNPs conjugated with S14P5 alone (LOD of 4.1 nM). Comparing between the two dual-epitope-functionalized AuNPs, the LODs of S14P5/S21P2-AuNPs are lower than those of S14P5/S20P2-AuNPs for the detection of anti-S1 and anti-S2 IgGs of SARS-CoV-2 (Figure 4b) .

To further optimize the nanosensor design for clinical sample detection, we evaluated the compatibility of epitopefunctionalized AuNPs in relevant biofluids by monitoring the sensor response upon exposure to SARS-CoV-2 IgG in different concentrations of human plasma. Both S14P5-AuNPs and dual-peptide-functionalized S14P5/S21P2-AuNPs were chosen as the model nanoparticles for this investigation due to their high sensitivity. In the case of S14P5/S21P2-AuNPs, nanosensor response against 100 nM anti-S1 IgG was attenuated with increasing concentrations of human plasma, from 78.2% in pure PBS to 22.8% and 14.6% in 10-fold and 5fold diluted human plasma, respectively (Figure 4c ). S14P5-AuNPs showed a similar trend in the modulation of sensor response with increasing plasma concentration (Figure 4c) . The diminished sensor response in high plasma background may be caused by nonspecific adsorption of plasma proteins to the nanosensor constructs, which subsequently hindered the binding of IgG to the epitopes on the AuNPs. To reduce the inhibitory effects of biofouling on nanosensor response, we passivated the surface of AuNPs with polyethylene glycol (PEG) moieties. The hydrodynamic diameters of PEGylated S14P5-AuNPs and S14P5/S21P2-AuNPs were similar to the nonpassivated counterparts ( Figure S8 ). The zeta potentials of these PEG-passivated AuNPs were less negative than the nonpassivated nanoparticles ( Figure S9 ). These trends indicate the successful conjugation of the neutrally charged PEG molecule, along with the epitopes, on the surface of SA-AuNPs. As biotinylated PEG and epitopes have similar molecular weights and their conjugation affinity toward SA-AuNPs is mainly governed by the streptavidin−biotin binding, we assumed a uniform distribution between PEG and epitopes on the nanoparticle surface. The PEG-passivated AuNPs recognized SARS-CoV-2 IgG with similar sensitivity to non-PEGylated AuNPs in PBS (Figure 4c) . Importantly, passivated nanosensors demonstrated enhanced sensitivity compared with the nonpassivated nanoparticles to SARS-CoV-2 IgG in human serum, with 46.5% and 35.2% sensor response in 10-fold and 5fold diluted serum, respectively, in the case of PEGylated S14P5/S21P2-AuNPs. These results suggest that PEG passivation of epitope-functionalized AuNPs partially mitigated nanosensor biofouling, strengthening the practical utility of epitope-functionalized nanosensors as in vitro diagnostic tools for SARS-CoV-2 IgG detection in plasma.

Sensitive and Selective SARS-CoV-2 IgG Detection in Clinical Samples. Finally, we utilized the PEG-passivated S14P5-AuNPs and S14P5/S21P2-AuNPs to detect SARS-CoV-2 IgG in clinical patient samples. In the first trial, a cohort of 20 clinical samples from Singapore, consisting of 10 PCRconfirmed COVID-19 samples of different severity at median 34.5 days pio and 10 healthy patient samples, was used to validate the assay utility. Plasma samples were inactivated with 1% (v/v) Triton X-100 prior to incubation with epitope-tagged AuNPs for 1 h. The final plasma concentration after mixing with AuNPs was 10% (v/v). From the 10 COVID-19-positive samples, the mono-epitope S14P5-AuNPs and dual-epitope S14P5/S21P2-AuNPs accurately detected 6 and 8 samples as positive, respectively (Figure 5a and b) . The higher sensitivity of the dual-epitope S14P5/S21P2-AuNPs could be attributed to the presence of both the S14P5 and S21P2 epitopes on the AuNP surface, enabling recognition of a wider range of SARS-CoV-2-specific IgGs (anti-S1 and anti-S2) present in COVID-19 plasma samples. This observation is consistent with earlier experiments using purified polyclonal SARS-CoV-2 antibodies (Figure 4a and b) . The 2 false negative samples which could not be detected with S14P5/S21P2-AuNPs were asymptomatic and mild cases, which are known to have decreased IgG levels. 56, 57 There was no false positive result from both types of nanoparticles. Encouraged by these preliminary results, we conducted a blind test using a cohort of 15 samples, of which 13 samples were PCR-confirmed COVID-19 samples of different severity (median 37 days pio) and 2 samples were obtained from healthy patients prior to the COVID-19 outbreak. For both mono-and dual-epitope nanosensors, the COVID-19-negative samples elicited a sensor response that was much lower than the previously defined cutoff (Figure 5a and b). As expected, the dual S14P5/S21P2-AuNPs showed a higher sensitivity than the mono S14P5-AuNPs, with successful detection of 11 and 9 positive cases from 13 COVID-19-positive samples by the former and the latter, respectively. Similar to the validation test, the two false negatives in the case of S14P5/S21P2-AuNPs were asymptomatic and mild cases. Overall, the sensitivity of S14P5-AuNPs and S14P5/S21P2-AuNPs was 65% and 83%, respectively, with 100% specificity for both nanoparticles when tested against 35 clinical patient samples. The high specificity and sensitivity of PEG-passivated S14P5/S21P2-AuNPs in clinical sample detection demonstrates the potential of this nanosensor platform to serve as promising alternatives to classical immunoassays in COVID-19 serodiagnostics.

In summary, we have developed a nanosensor platform for rapid detection of SARS-CoV-2 antibodies by exploiting specific epitope−IgG interactions. This assay harnesses the innate ability of specific linear B-cell epitopes to selectively recognize SARS-CoV-2 IgG, together with the distancedependent plasmonic properties of AuNPs. Prior to nanosensor preparation, we determined the binding affinity and specificity of four immunodominant linear B-cell epitopes toward SARS-CoV-2 IgG with SPR and FP characterization tools. A generic SA-mediated conjugation of the epitopes to AuNPs was developed to produce nanosensors that can recognize cognate SARS-CoV-2 IgG antibodies, detectable as changes in the absorption spectra of AuNPs. The epitopefunctionalized AuNPs showed nM-range LODs in recognizing SARS-CoV-2 IgG, with S14P5-AuNPs and S21P2 AuNPs being the most sensitive and N4P5-AuNPs being the least sensitive nanoparticles, which is in accordance with the binding affinity trend as determined by SPR and FP techniques in this study. Compared to single-epitope-functionalized AuNPs, the attachment of two pM-affinity epitopes (S14P5 and S21P2) on the AuNP surface further enhanced the sensitivity of the assay to the low nM range and expanded the detection capability to recognize SARS-CoV-2 IgGs targeting different regions of the viral antigen. Furthermore, passivation of the nanosensor surface with PEG enhanced the assay sensitivity in human plasma. Notably, PEGylated S14P5/S21P2-functionalized AuNPs could detect SARS-CoV-2 IgGs in the plasma samples from COVID-19 convalescent patients and discriminate between COVID-19-positive and -negative samples. As these four epitopes are conserved within the circulating COVID-19 variants, the proposed platform holds great potential to serve as highly specific and cost-effective serodiagnostics to control the current pandemic. The nanosensor design described here is also amenable to facile conjugation of different biotinylated epitopes or biomolecules to combat new mutations or future infectious disease outbreaks. More detailed studies on the effect of nanoparticle size, core metal compositions, and signal amplification strategies can be explored, offering further control on the dynamic range and sensitivity to tune analytical performance. Optimization of this nanosensor platform for IgG detection in other biofluids, such as saliva samples, can also be pursued to enable noninvasive and easy-to-scale serological testing at the point of care. 58 Taken together, the results presented in this work highlight the potential utility of epitopefunctionalized AuNPs in vaccine efficiency assessments, seroprevalence surveys, and targeted immunoassays to identify individuals with both late-stage and past SARS-CoV-2 infections, expanding the current tool box available for SARS-CoV-2 serodiagnosis. ACS Nano www.acsnano.org Article

Materials. Gold(III) chloride trihydrate (HAuCl 4 ·3H 2 O), sodium citrate dihydrate, sodium hydroxide, boric acid, N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES), phosphate-buffered saline (PBS), IgG from normal human serum, and normal human plasma were purchased from Sigma-Aldrich. Streptavidin (from Streptomyces avidini) was purchased from Thermo Fisher Scientific. Biotinylated and FITC-labeled peptide epitopes were purchased from Singapore Advanced Biologics Pte Ltd. PEG-biotin (MW = 2000 Da) was purchased from Biochempeg Scientific Inc. (Watertown, MA, USA). SARS-CoV-2 S1, S2, and N IgGs, SARS-CoV S and N IgGs, MERS S and N IgGs, and HCoV-HKU1 S and N IgGs were purchased from Sino Biological (Wayne, PA, USA). All reagents were used as received without further purification.

Characterization of Epitopes Using SPR Spectroscopy. SPR studies were performed using Biacore T200 (Cytiva). Streptavidin, at concentrations of 100 and 5 μg/mL in sodium acetate buffer pH 5 for kinetics and steady-state affinity experiments, respectively, was immobilized on a CM5 chip through EDC/NHS coupling at a flow rate of 10 μL/min. Biotinylated peptide epitopes were then immobilized on the SA-functionalized CM5 chip. Specifically, peptides were diluted in HEPES buffer saline (10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.05% polysorbate 20, pH 7.4) and subsequently injected to the SA-CM5 surface at a concentration ranging from 10 to 100 μg/mL with a flow rate of 10 μL/min. One flow cell was injected with buffer instead of peptides to serve as a reference flow cell. IgG diluted in HEPES buffered saline (HBS) at concentrations ranging from 0.1 to 80 μg/mL (for kinetics experiments) and from 6.25 to 3000 nM (for steady-state affinity experiments) was injected over the immobilized peptide surface and reference surface at a flow rate of 30 μL/min (for kinetics experiments) and 10 μL/min (for steady-state affinity experiments) at a temperature of 25°C. The complex was allowed to associate (300 s for kinetics experiments and 600 s for steady-state affinity experiments) and dissociate for 600 s. At the end of each cycle of IgG binding, the surfaces were regenerated with a 120 s injection of glycine HCl (pH 1.5). One sample was injected in duplicate over both surfaces to check the quality of the peptide-functionalized surface. Several buffer blanks were also injected intermittently over the course of an experiment for double referencing. Data processing and analysis were performed using Biacore T200 Evaluation Software version 2.0. A double-referencing method was performed to process all data sets. Data from the sample flow cell were referenced first by subtracting data from the reference flow cell to correct for bulk refractive index changes, nonspecific binding, injection noise, matrix effects, and baseline drift. Reference-subtracted data were double-referenced with a blank injection of running buffer to account for any systematic drift over the course of the injection. Double-referenced data were fit to a 1:1 Langmuir binding model for kinetic analysis or steady-state affinity model. Reported values are the mean and standard deviation of at least three independent experiments.

Characterization of Epitopes Using FP Technique. Black 384well polystyrene plates were used for FP characterization. In each reaction well, FITC-labeled epitope and the respective SARS-CoV-2 IgG were added with final concentrations of 100 and 200 nM, respectively, in 1× PBS with a total volume of 50 μL. The mixture was then kept in the dark for 15 min at room temperature. FP readings were obtained using a microplate reader (Synergy 2; BioTek) with an excitation of 485 nm and emission of 528 nm. FP values of FITClabeled epitopes alone (without IgG) were used as a baseline to evaluate the extent of FP increase upon IgG binding, using eq 1 below: (1)

Preparation of Epitope-Functionalized AuNPs. Citratecapped AuNPs of approximately 13 nm diameter were synthesized by the citrate reduction method as described previously. 59 Briefly, an aqueous solution of HAuCl 4 (1 mM, 50 mL) was brought to reflux while stirring, and then a solution of sodium citrate (38.8 mM, 5 mL) was added quickly. After the solution color changed from pale yellow to deep red, the solution was refluxed for another 20 min and allowed to cool to room temperature. The resulting solution of citrate-AuNPs was stored at 4°C overnight before further use.

Prior to functionalization with SA and biotinylated epitopes, the citrate buffer of as-prepared AuNPs was exchanged to a borate buffer (pH 8.0, 100 mM, 0.05% Tween) by centrifugation. Then, 10 μL of SA (1 mg/mL in pH 8.0 borate buffer) was added to 500 μL of AuNP solution. The mixture was vortexed briefly and stirred at room temperature for 2 h. Excess SA was removed by centrifugation at 12500g for 15 min. The pellet was resuspended in borate buffer, and a solution of biotinylated peptide epitope (20 μL, 20 μM) was added to 500 μL of SA-AuNPs. In the case of PEGylated or binary epitopecapped AuNPs, equal volumes of PEG-biotin or biotinylated epitopes (20 μM) were introduced such that the total volume of biotinylated molecules was 20 μL. The mixture was stirred at room temperature for 30 min before centrifugation at 12500g for 15 min to remove excess biotinylated molecules. The final conjugates were then resuspended in HEPES buffer (pH 7.5, 5 mM) to prepare epitopefunctionalized AuNPs for further use. The hydrodynamic diameter and zeta potential of AuNPs at different preparation stages were characterized with Zetasizer Nano ZS (Malvern).

Immunoassay Procedure with Epitope-Tagged AuNPs. SARS-CoV-2 IgG antibodies and control antibodies were first diluted in 1× PBS. In a typical experiment, 5 μL of prediluted antibody solution was added to 45 μL of epitope-functionalized AuNPs. The mixture was spun briefly for 20 s at 6000 rpm using a portable microcentrifuge (Profuge 6K) and incubated for another 30 min at room temperature. Absorbance spectra of the supernatant were recorded using a microplate reader (Synergy 2; BioTek). Sensor response was calculated as the relative change in absorbance at 534 nm. For a time-profile study, the absorbance spectra were recorded at 10 min intervals. For a salt-induced aggregation test, solutions of AuNPs were treated with 1× PBS and the absorbance spectra were recorded after a 30 min incubation. For a selectivity screen against other human coronaviruses, the concentration of antibodies was 100 nM. To investigate the sensitivity of AuNPs in human plasma, SARS-CoV-2 IgG rabbit antibodies were spiked into PBS containing various concentrations of human plasma, such that the final plasma concentration after mixing with AuNPs was 0%, 10%, and 20% (v/v).

Ethics Approvals. The study design and protocols for COVID-19 patients were evaluated by National Healthcare Group (NHG) Domain Specific Review Board (DSRB) and approved under study number 2012/00917. Healthy donor samples were collected prior to the COVID-19 outbreak under study numbers 2017/2806 and NUS IRB 04-140. Written informed consent was obtained from participants in accordance with the Declaration of Helsinki for Human Research.

Detection of SARS-CoV-2 IgG in Clinical Samples. A total of 23 COVID-19 patients who tested PCR-positive for SARS-CoV-2 in nasopharyngeal swab samples were classified into four groups based on their clinical severity: asymptomatic (no symptoms of COVID- 19) , mild (no pneumonia on chest radiographs (CXR) at baseline and during hospital admission), moderate (pneumonia on CXR without hypoxia), and severe (pneumonia on CXR with hypoxia [desaturation to ≤94%]). Whole blood of patients was collected in BD Vacutainer cell preparation tubes (BD Biosciences) and centrifuged at 1700g for 20 min to obtain plasma fractions. Samples were then treated with 1% Triton X-100 (ThermoFisher Scientific) for 2 h at room temperature for virus inactivation. A 5 μL amount of the undiluted, inactivated plasma samples was then mixed with 45 μL of PEG-passivated epitope-tagged AuNPs for immunoassay analysis as described in the previous section, such that the final plasma concentration was 10% (v/v). The threshold for detection was calculated from the mean nanosensor responses elicited by healthy patient samples + 3 standard deviations.

ACS Nano www.acsnano.org Article

Opportunities and Challenges for Biosensors and Nanoscale Analytical Tools for Pandemics: COVID-19

Antibody Responses to SARS-CoV-2 in Patients with COVID-19

Patterns of IgG and IgM Antibody Response in COVID-19 Patients. Emerging Microbes Infect. 2020

The Important Role of Serology for COVID-19 Control

Developing Antibody Tests for SARS-CoV-2

A Multiplex Chemiluminescent Immunoassay for Serological Profiling of COVID-19-Positive Symptomatic and Asymptomatic Patients

Testing for SARS-CoV-2 (COVID-19): A Systematic Review and Clinical Guide to Molecular and Serological In-Vitro Diagnostic Assays

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses during Infection by SARS-CoV-2: An Observational Cohort Study

Evidence for Antibody as a Protective Correlate for COVID-19 Vaccines

Immunological Surrogate Endpoints of COVID-2019 Vaccines: The Evidence We Have versus the Evidence We Need

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses

Antigen Arrays for Profiling Autoantibody Repertoires

Deciphering the Antibodyome -Peptide Arrays for Serum Antibody Biomarker Diagnostics

The Role of Peptide Microarrays in Biomedical Research

Assay Techniques and Test Development for COVID-19 Diagnosis

Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath

Toward Rapid and Sensitive Detection of SARS-CoV-2 with Functionalized Magnetic Nanoparticles

Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics

Diagnostics for SARS-CoV-2 Infections

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

One-Step Rapid Quantification of SARS-CoV-2 Virus Particles via Low-Cost Nanoplasmonic Sensors in Generic Microplate Reader and Point-of-Care Device

How Nanophotonic Label-Free Biosensors Can Contribute to Rapid and Massive Diagnostics of Respiratory Virus Infections: COVID-19 Case

Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs

Rapid Detection of IgM Antibodies against the SARS-CoV-2 Virus via Colloidal Gold Nanoparticle-Based Lateral-Flow Assay

Development of a Lateral Flow Immunoassay Strip for Rapid Detection of IgG Antibody against SARS-CoV-2 Virus

Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay

Development of a Sensitive Immunochromatographic Method Using Lanthanide Fluorescent Microsphere for Rapid Serodiagnosis of COVID-19

Development and Clinical Application of a Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis

Comparison of Three Indirect Immunoassay Formats on a Common Paper-Based Microfluidic Device Architecture

Vertical Flow Cellulose-Based Assays for SARS-CoV-2 Antibody Detection in Human Serum

ExPASy: The Proteomics Server for In-Depth Protein Knowledge and Analysis

) Tamada, K. Surface Plasmon Resonance. In Compendium of Surface and Interface Analysis; The Surface Science Society

A Surface Plasmon Resonance-Based Assay to Measure Serum Concentrations of Therapeutic Antibodies and Anti-Drug Antibodies

Insights into PARP Inhibitors' Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays

Fluorescence Polarization (FP) Assays for Monitoring Peptide-Protein or Nucleic Acid-Protein Binding

Analysis of Protein-Ligand Interactions by Fluorescence Polarization

Rational Design of Functional Peptide−Gold Hybrid Nanomaterials for Molecular Interactions

Bioresponsive Peptide−Inorganic Hybrid Nanomaterials

Factors Determining the Efficacy of Nuclear Delivery of Antisense Oligonucleotides by Gold Nanoparticles

Streptavidin-Coated Gold Nanoparticles: Critical Role of Oligonucleotides on Stability and Fractal Aggregation

Nanoscale Surface-Induced Unfolding of Single Fibronectin Is Restricted by Serum Albumin Crowding

On the Universal Scaling Behavior of the Distance Decay of Plasmon Coupling in Metal Nanoparticle Pairs: A Plasmon Ruler Equation

Nanomaterial-Based Biosensors Using Dual Transducing Elements for Solution Phase Detection

Step Homogeneous Immunoassays Utilizing Epitope-Tagged Gold Nanoparticles: On the Mechanism, Feasibility, and Limitations

COVID-19 Diagnosis and Study of Serum SARS-CoV-2 Specific IgA, IgM and IgG by Chemiluminescence Immunoanalysis. medRxiv, 2020

Humoral Responses and Serological Assays in SARS-CoV-2 Infections

Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections

Systemic and Mucosal Antibody Responses Specific to SARS-CoV-2 during Mild versus Severe COVID-19

Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions

This work was supported by the Singapore National Medical Research Council (NMRC) COVID-19 Research Fund (#COVID19RF3-0054 and #COVID19RF-001) and by the Agency of Science, Technology and Research (A*STAR) funding. The authors would like to thank the study participants who donated their blood samples to this study. The authors also wish to thank Ding Ying, Dr. Barnaby Edward Young, Prof. David C. Lye, and Prof. Yee-Sin Leo and the team at the National Centre for Infectious Diseases (NCID), Dr. Seow-Yen Tan and team at Changi General Hospital, and Singapore Infectious Disease Clinical Research Network (SCRN) for their help in patient recruitment.